1. Braf-MUTATION POSITIVE melanoma: a case conference

3. This Program Will Discuss

4. Program Format: Case Discussions

5. Case #1: Background

6. Case #1: Management

7. Dabrafenib + Trametinib vs Dabrafenib Phase 2 Study Results

8. Dabrafenib/Trametinib: AEs

9. BRAF/MEK Inhibitors: AEs Grade ≥2

10. COMBI-d: Dabrafenib + Trametinib vs Dabrafenib + Placebo

11. COMBI-v: Dabrafenib + Trametinib Vs Vemurafenib

12. coBRIM: Vemurafemib + Cobimetinib vs Vemurafenib + Placebo

13. Vemurafenib/Cobimetinib: AEs

14. When Do You Stop Therapy?

15. Case #2: Background

16. Case #2 – Initial Imaging January 2013

17. Case #2: Initial Management

18. Case #2: Follow-up Imaging

19. Case #2: Adding a MEK Inhibitor

20. Case #2: Local Progression

21. Case #2: New AE

22. Treatment Beyond Progression

23. Case #3: Background

24. Case #3: Second-line BRAF/MEK Therapy

25. Second-line Vemurafenib Phase 2 Study Results

26. Treatment Sequencing

27. Case #4: Background

28. Case #4 – Management

29. Case #4: Response

30. Case #4: New AE

31. Maximizing Treatment Outcomes

32. Maximizing Patient Quality of Life EORTC QLQ-C30 Global Health Status Score

33. Conclusions

34. Abbreviations

35. Abbreviations (cont)